HCRN-BRE18-360
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Status: Open to Accrual
Learn more:
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter